Kwality Pharmaceuticals Ltd

As of June 30, 2026, Kwality Pharmaceuticals Ltd carries a market capitalization of 29.06B, placing it among publicly traded companies globally. Its enterprise value stands at 29.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Kwality Pharmaceuticals Ltd has 10.38M shares outstanding.

As of June 30, 2026, Kwality Pharmaceuticals Ltd trades at a trailing price-to-earnings ratio of 35.87.

As of June 30, 2026, Kwality Pharmaceuticals Ltd trades at an EV/EBITDA multiple of 21.65 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.25 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 25.45 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 29.06B versus a market cap of 29.06B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 5.19M in revenue per employee across its workforce of 1,067.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Kwality Pharmaceuticals Ltd recorded 254.03M in income tax expense. That works out to an effective tax rate of 23.86, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.06B, leaving 810.51M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Kwality Pharmaceuticals Ltd's stock has gained approximately 305.27% over the past 52 weeks. The 50-day moving average sits at 3,497.33, while the 200-day moving average is 2,248.56.

Over the twelve months ended June 30, 2026, Kwality Pharmaceuticals Ltd generated 5.54B in revenue and converted that into 810.51M in net income, yielding earnings per share of 78.09. EBITDA reached 1.34B, while operating income came in at 1.15B.

Over the twelve months ended June 30, 2026, Kwality Pharmaceuticals Ltd posted a gross margin of 48.04, reflecting its pricing power and cost economics. The operating margin of 20.77 and net profit margin of 14.63 provide insight into operational efficiency.

Kwality Pharmaceuticals Ltd's most recent stock split took place on October 11, 2017 with a 1:2 split ratio.